Evidence map›Paper›PMID 36056435›Full record

ArticleMolecular neurodegeneration2022

Trem2 deletion enhances tau dispersion and pathology through microglia exosomes.

Bing Zhu, Yan Liu, Spring Hwang, Kailey Archuleta, Huijie Huang, Alex Campos, Rabi Murad, Juan Piña-Crespo, Huaxi Xu, Timothy Y Huang

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Article
  3. TREM2 in neurodegeneration and diseases.Molecular psychiatry · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Extracellular Vesicles in Tauopathies: Mechanisms and Applications.International journal of molecular sciences · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Observational
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Bing Zhu *Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Yan Liu *Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Spring HwangDegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Kailey ArchuletaDegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Huijie HuangDegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Alex CamposProteomics Facility Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Rabi MuradBioinformatics Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Juan Piña-CrespoDegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Huaxi XuPresent address: Institute for Brain Science and Disease, Chongqing Medical University, Chongqing, China. huaxi.xu@molneurodegener.org.
Timothy Y HuangDegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA. thuang@sbpdiscovery.org.ORCID 0000-0002-3504-9459
Sanford Burnham Prebys Medical Discovery Institute · USChongqing Medical University · CN

Funding

Molecular pathobiology of soluble TREM2 in Alzheimer's disease.RF1AG056130 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, TIMOTHY YIKAI, ZHAO, NA · 2017 to 2023
$6.8M
Characterizing a potential role for TREM2 in modulating tau pathogenesis in response to AbetaR21AG070676 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, TIMOTHY YIKAI · 2021 to 2022
$536k
NIA NIH HHS R21 AG070676NIA NIH HHS RF1 AG056130
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a neurodegenerative disorder that manifests sequential Aβ and tau brain pathology with age-dependent onset. Variants in the microglial immune receptor TREM2 are associated with enhanced risk of onset in sporadic Alzheimer's disease (AD). While recent studies suggest TREM2 dysfunction can aggravate tau pathology, mechanisms underlying TREM2-dependent modulation of tau pathology remains elusive.

methodsHere, we characterized differences in progressive tau spreading from the medial entorhinal cortex (MEC) to the hippocampus in wildtype (WT) and Trem2 knockout (KO) mice by injection of AAV-P301L tau into the MEC, and correlated changes in hippocampal tau histopathology with spatial and fear memory. We also compared effects of intraneuronal dispersion between cultured microglia and neurons using a microfluidic dispersion assay, analyzed differences in microglial tau trafficking following uptake, and quantified exosomal tau secretion and pathogenicity from purified WT and Trem2 KO exosomes.

resultsTrem2 deletion in mice (Trem2 KO) can enhance tau spreading from the medial entorhinal cortex (MEC) to the hippocampus, which coincides with impaired synaptic function and memory behavior. Trem2 deletion in microglia enhances intraneuronal dispersion of tau in vitro between neuronal layers cultured in a microfluidic chamber, and the presence of exosome inhibitors can significantly reduce tau in exosomes and extracellular media from tau-loaded microglia. Although microglial Trem2 deletion has no effect on tau uptake, Trem2 deletion enhances distribution to endosomal and cellular pre-exosomal compartments following internalization. Trem2 deletion has little effect on exosome size, however, proteomic analysis indicates that Trem2 deletion can modulate changes in the microglial proteomic landscape with tau and LPS/ATP treatment conditions associated with exosome induction. Furthermore, exosomes from Trem2 KO microglia show elevated tau levels, and feature enhanced tau-seeding capacity in a tau FRET reporter line compared to exosomes from WT microglia.

conclusionTogether, our results reveal a role for Trem2 in suppressing exosomal tau pathogenicity, and demonstrates that Trem2 deletion can enhance tau trafficking, distribution and seeding through microglial exosomes.

Indexed as

Alzheimer DiseaseExosomesAnimalsMembrane GlycoproteinsMiceMice, KnockoutMicrogliaProteomicsReceptors, ImmunologicMembrane GlycoproteinsReceptors, ImmunologicTrem2 protein, mouseAlzheimer’s diseaseExosomesMicrogliaTau pathologyTau spreadingTrem2

Identifiers

PMID36056435
PMCPMC9438095
OpenAlexW4294169024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.